Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer

Abstract

Endocrine treatment represents the cornerstone of endocrine-sensitive premenopausal early breast cancer. The estrogen blockade plays a leading role in the therapeutic management of hormone receptor-positive breast cancer together with surgery, radiotherapy, and selective antiestrogen treatments. For several years, selective estrogen receptor modulators, such as tamoxifen, have represented the mainstay of therapy. The role of amenorrhea has been extensively elucidated in the past year: the benefit observed with chemotherapy-induced amenorrhea has strengthened its therapeutic role. Luteinizing hormone-releasing hormone (LHRH) has been introduced in oncology practice to induce amenorrhea in order to increase the advantage obtained from endocrine treatment. Triptorelin is one of the most widely used LHRH analogs currently available in clinical practice. It was recently investigated in two major clinical trials that studied the role of complete estrogen blockade in the premenopausal setting. Both showed the clinical benefit due to ovarian suppression treatment, primarily in high-risk patients. Furthermore, triptorelin and other LHRH analogs have recently been investigated in the attempt to preserve the ovarian function in young patients. The medical treatment of early breast cancer is always evolving in the effort to search for safe and efficacious treatments. The role of LHRH analogs is actually well recognized as contributing to the improvement of the medical treatment of premenopausal women with early breast cancer.

Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling

“…Discovering the prominent role of CTGF during breast cancer invasion by modifying cell adhesion, ECM degradation and FN1 expression, we wanted to test if CTGF can be targeted and elucidated molecular mechanism by which CTGF can be repressed to suppress cell dissemination and colonization at distant sites. We found that GnRH agonist Triptorelin, which is in clinical use for ovarian function suppression of premenopausal breast cancer with high clinical risk of recurrence 28 , and was demonstrated to reduce breast cancer invasion 37 , reduced CTGF expression in mesenchymal transformed breast cancer in a dose-dependent manner. Furthermore, we found that CTGF was downregulated by Triptorelin treatment in TNBC cells.…”

“…Suppression of ovarian function is part of therapy of endocrine-sensitive premenopausal early and advanced hormone receptorpositive breast cancer. Triptorelin, a GnRH agonist, revealed clinical benefit in high-risk patients by suppressing ovarian steroids and it has been investigated in attempt to preserve ovarian function during chemotherapy in young female patients 28 . GnRH receptor is expressed in 50-64% of all human breast cancers [29][30][31][32][33] .…”

Development of Identification Test Methods for Triptorelin Acetate and Goserelin Acetate Substances using NMR spectroscopy

“…1). Они активно применяются при лечении злокачественных новообразований в области репродуктивной системы и гинекологических заболеваний, связанных с нарушением эндокринной регуляции [4][5][6][7][8][9].…”

“…1). They are widely used in the treatment of malignant tumours of the reproductive system and gynecological diseases associated with endocrine regulation disorders [4][5][6][7][8][9].…”

The Problem of Dynamic Process Manifestation in Identification of Organic Compounds by NMR Spectroscopy

“…Например, в молекулах бусерелина, гозерелина и трипторелина присутствует прототропная таутомерия в 4-замещенном имидазоле гистидинового фрагмента. Эти соединения являются синтетическими аналогами гонадолиберина и активно применяются при лечении злокачественных новообразований в области репродуктивной системы и гинекологических заболеваний, связанных с нарушением эндокринной регуляции [47][48][49][50][51]. 4 протонного обмена N-H…N в интегральную скорость миграции протона до критического уровняскорость прототропной таутомерии замедляется.…”